Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood) [clinicaltrials_resource:NCT00772447/outcome/1]
outcome [clinicaltrials_vocabulary:outcome]
Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood) [clinicaltrials_resource:NCT00772447/outcome/1]
Bio2RDF identifier
NCT00772447/outcome/1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00772447/outcome/1
group [clinicaltrials_vocabulary:group]
measure [clinicaltrials_vocabulary:measure]
population [clinicaltrials_vocabulary:population]
ME population includes all the ...... n comparator arm(79 patients).
ME population includes all the ...... of ME population at EOT visit.
Only patients who had both mea ...... ary. Change=TOC visit-baseline
Only patients who had measurem ...... sis. Change=TOC visit-baseline
Only patients who had measurem ...... Change = TOC visit - baseline
There were 107 patients in dap ...... ation and completed TOC visit.
There were 110 patients in dap ...... the criteria of CE population
There were 14 patients indenti ...... with MRSA in comparator group.
There were 33 patients indenti ...... with MSSA in comparator group.
There were 48 patients indenti ...... group and in comparator group.
safety issue [clinicaltrials_vocabulary:safety-issue]
time frame [clinicaltrials_vocabulary:time-frame]
baseline and EOT(end of therapy), for up to 2 weeks
baseline and EOT, for up to 2 weeks
baseline and TOC(test of cure), for up to 4 weeks
baseline and TOC, for up to 4 weeks
baseline to TOC(test of cure), for up to 4 weeks
type [clinicaltrials_vocabulary:type]
alternate
Change of Erythrocyte Volume F ...... lume in Total Volume of Blood)
@en
identifier
clinicaltrials_resource:NCT00772447/outcome/1
title
Erythrocyte volume fraction me ...... e in the total volume of blood
@en
type
label
Change of Erythrocyte Volume F ...... esource:NCT00772447/outcome/1]
@en